Evidence map›Paper›PMID 26483137›Full record

ArticleBioorganic & medicinal chemistry letters2015

Chemical conjugation of 2-hexadecynoic acid to C5-curcumin enhances its antibacterial activity against multi-drug resistant bacteria.

David J Sanabria-Ríos, Yaritza Rivera-Torres, Joshua Rosario, Ricardo Gutierrez, Yeireliz Torres-García, Nashbly Montano, Gabriela Ortíz-Soto, Eddy Ríos-Olivares, José W Rodríguez, Néstor M Carballeira

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Synthesis of the NovelACS omega · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

David J Sanabria-RíosFaculty of Science and Technology, Inter American University of Puerto Rico, Metropolitan Campus, PO Box 191293, San Juan 00919, Puerto Rico. Electronic address: dsanabria@intermetro.edu.
Yaritza Rivera-TorresFaculty of Science and Technology, Inter American University of Puerto Rico, Metropolitan Campus, PO Box 191293, San Juan 00919, Puerto Rico.
Joshua RosarioFaculty of Science and Technology, Inter American University of Puerto Rico, Metropolitan Campus, PO Box 191293, San Juan 00919, Puerto Rico.
Ricardo GutierrezFaculty of Science and Technology, Inter American University of Puerto Rico, Metropolitan Campus, PO Box 191293, San Juan 00919, Puerto Rico.
Yeireliz Torres-GarcíaFaculty of Science and Technology, Inter American University of Puerto Rico, Metropolitan Campus, PO Box 191293, San Juan 00919, Puerto Rico.
Nashbly MontanoDepartment of Chemistry, University of Puerto Rico, Rio Piedras Campus, PO Box 23346, San Juan 00931-3346, Puerto Rico.
Gabriela Ortíz-SotoDepartment of Microbiology and Immunology, Universidad Central del Caribe School of Medicine, PO Box 60327, Bayamón 00960, Puerto Rico.
Eddy Ríos-OlivaresDepartment of Microbiology and Immunology, Universidad Central del Caribe School of Medicine, PO Box 60327, Bayamón 00960, Puerto Rico.
José W RodríguezDepartment of Microbiology and Immunology, Universidad Central del Caribe School of Medicine, PO Box 60327, Bayamón 00960, Puerto Rico.
Néstor M CarballeiraDepartment of Chemistry, University of Puerto Rico, Rio Piedras Campus, PO Box 23346, San Juan 00931-3346, Puerto Rico.
InterAmerican University of Puerto Rico · PRCentral University of the Caribbean · PRUniversity of Puerto Rico at Río Piedras · PR

Funding

SCIENCE AND TECHNOLOGY COMPETENCY & EDUCATION CORE (STCE)P20GM103475 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Humberto Guillermo Ortiz-Zuazaga · 2012 to 2026
$52.9M
TECHNOLOGIES AND RESOURCES FOR CORE LABORATORIESU54MD007587 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI BENABE, JULIO E, LUCIANO, CARLOS A. · 2012 to 2018
$23.2M
UNIVERSIDAD CENTRAL DEL CARIBE BIOMEDICAL RESEARCH CENTERSG12MD007583 · NIMHD · UNIVERSIDAD CENTRAL DEL CARIBE · PI RODRIGUEZ, JOSE GINEL · 2012 to 2016
$8.4M
TRCLU54RR026139 · NCRR · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FRONTERA, WALTER R. · 2010 to 2011
$8.4M
NCRR NIH HHS U54 RR026139NIGMS NIH HHS 5 P20 GM103475-13NIGMS NIH HHS P20 GM103475NIMHD NIH HHS 8G12MD007583-28NIMHD NIH HHS 8U54MD 007587-03NIMHD NIH HHS G12 MD007583NIMHD NIH HHS U54 MD007587
6 · The paper itself

Abstract

The first total synthesis of a C5-curcumin-2-hexadecynoic acid (C5-Curc-2-HDA, 6) conjugate was successfully performed. Through a three-step synthetic route, conjugate 6 was obtained in 13% overall yield and tested for antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains. Our results revealed that 6 was active against eight MRSA strains at MICs that range between 31.3 and 62.5 μg/mL. It was found that the presence of 2-hexadecynoic acid (2-HDA, 4) in conjugate 6 increased 4-8-fold its antibacterial activity against MRSA strains supporting our hypothesis that the chemical connection of 4 to C5-curcumin (2) increases the antibacterial activity of 2 against Gram-positive bacteria. Combinational index (CIn) values that range between 1.6 and 2.3 were obtained when eight MRSA strains were treated with an equimolar mixture of 2 and 4. These results demonstrated that an antagonistic effect is taking place. Finally, it was investigated whether conjugate 6 can affect the replication process of S. aureus, since this compound inhibited the supercoiling activity of the S. aureus DNA gyrase at minimum inhibitory concentrations (MIC) of 250 μg/mL (IC50=100.2±13.9 μg/mL). Moreover, it was observed that the presence of 4 in conjugate 6 improves the anti-topoisomerase activity of 2 towards S. aureus DNA gyrase, which is in agreement with results obtained from antibacterial susceptibility tests involving MRSA strains.

Indexed as

AlkynesAnimalsAnti-Bacterial AgentsChlorocebus aethiopsCurcuminDNA GyraseDNA, SuperhelicalEscherichia coliFatty Acids, UnsaturatedHumansLeukocytes, MononuclearMethicillin-Resistant Staphylococcus aureusStaphylococcus aureusTopoisomerase II InhibitorsVero Cells2-hexadecynoic acidAlkynesAnti-Bacterial AgentsC5-curcumin-2-hexadecynoic acidCurcuminDNA GyraseDNA, SuperhelicalFatty Acids, UnsaturatedTopoisomerase II InhibitorsAntagonismAntibacterial agentsC5-curcuminoids synthesisDNA gyraseMRSA

Identifiers

PMID26483137
PMCPMC4663078
OpenAlexW1895054144

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.